Loading
Michael Yu founded Innovent in Suzhou in 2011 and made sintilimab one of China's best-selling cancer drugs before turning the company into a supplier of new medicines to Roche and Takeda.
Yu earlier co-invented Oncorine (H101), the world's first approved oncolytic virus (China, 2005), and the anti-VEGF conbercept; at Innovent he built an integrated antibody company with sintilimab, four biosimilars, the CAR-T eque-cel partnership, KRAS G12C inhibitor fulzerasib and the IBI363 and IBI343 programmes licensed to Takeda in 2025.
Shares Equecabtagene autoleucel, Innovent Biologics and the tag china.
Shares Equecabtagene autoleucel, Innovent Biologics and the tag china.
Shares Innovent Biologics, Sintilimab and the tag china.
Shares Innovent Biologics, Sintilimab and the tag china.
Shares Innovent Biologics, Sintilimab and the tag china.
Shares Oncolytic viruses and the tag china.
Shares Sintilimab and the tag china.
Shares Fulzerasib, Innovent Biologics and the tag china.